# A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

> **NCT03522142** · PHASE1 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 83 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** INCB081776
- **DRUG:** INCMGA00012

## Key facts

- **NCT ID:** NCT03522142
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-27
- **Primary completion:** 2025-09-10
- **Final completion:** 2025-09-10
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** The study was terminated after careful review of the overall clinical activity of this compound and a lack of robust efficacy. The study closure is not based on safety concerns.
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03522142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03522142, "A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03522142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*